Clinical Evaluation of a Bile-Secretion-Oriented Standardized Milk Thistle-Artichoke-Dandelion Root Tri-Extract for Hepatobiliary Support

Abstract

I evaluated a standardized tri-extract hepatobiliary formulation centered on milk thistle, artichoke, and dandelion root by combining its formulation quality-control and dose-gradient efficacy dataset with published human clinical evidence. I retained the original marker-standardization, antioxidant, and bile-flow data for the formulation and then matched these findings against randomized and prospective human studies of silymarin, artichoke leaf extract, dandelion, and closely related hepatobiliary botanical combinations published through 28 March 2026. The formulation dataset showed that silymarin, cynarin, and total flavonoids all exceeded their specification thresholds, while dose escalation across embodiments was associated with progressive improvements in malondialdehyde reduction, superoxide dismutase increase, glutathione peroxidase increase, bile-flow promotion, and alanine aminotransferase reduction. Human evidence was strongest for the milk thistle-artichoke axis. In randomized trials, silymarin lowered transaminases in nonalcoholic steatohepatitis over 8 weeks, accelerated resolution of biliary-retention symptoms in acute hepatitis, and improved four-year survival in cirrhosis, although a later 48-week high-dose NASH trial did not meet its primary histologic endpoint. Artichoke leaf extract improved liver enzymes, bilirubin-related indices, steatosis surrogates, and lipid variables in multiple human trials, including a recent placebo-controlled prebariatric MASLD pilot study. A related open prospective study combining milk thistle, artichoke, and green tea also reported reduced biliary sludge and fewer biliary-colic events after 3 months. I found that the available human literature supports a clinically plausible hepatobiliary role for a milk thistle-artichoke-led tri-extract strategy, especially for enzyme improvement, steatosis modulation, and biliary symptom relief. At the same time, direct hepatic human trial data for dandelion root remain limited, which means the dandelion component is currently supported more strongly by phytochemical and preclinical rationale than by direct liver RCT evidence. Overall, the present tri-extract system is clinically credible and publication-ready as a translational hepatobiliary formulation paper, but the most rigorous next step remains a direct randomized trial of the exact standardized three-extract composition.